Developer docs
API playgroundTry for free, no card

Search company profiles

Yuuwa Capital

Full company profile

uuid000eui4

Namestring
Yuuwa Capital
Legal namestring
Yuuwa
Websiteurl
yuuwa.com.au
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Yuuwa Capital is a specialist early-stage life sciences commercialisation and investment firm headquartered in Perth, Western Australia, founded in 2009. The firm was originally established as the manager of a $40 million venture capital fund with capital from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. Its stated function is to identify new projects, help founders and management teams start and scale companies in the life sciences sector, and connect specialist early-stage investors to high-quality life sciences ventures. There are no proprietary technology products or services — the "product" is the fund vehicle and the firm's operational support to portfolio companies.

Operationally, Yuuwa provides both capital and hands-on commercialisation expertise: direct equity investment, board representation, and ongoing portfolio support spanning concept-to-commercialisation activities. The team is led by co-founders Liddy McCall and James Williams, with documented track records including the founding of iCeutica Inc (acquired in 2011), co-founding and chairing ASX-listed Dimerix Limited (DXB), involvement in five FDA approved drugs and devices, board roles at AdAlta Limited (ASX:1AD), Argenica Ltd (ASX:AGN), Agworld Pty Ltd, Fitgenes Australia Limited, PolyActiva Pty Ltd, the Ear Science Institute of Australia, and the Perron Institute for Neurological and Translational Science. The disclosed portfolio comprises AdAlta, Agworld, Fitgenes, iCentana, Nexgen Plants, and PolyActiva.

Yuuwa's revenue model is that of a venture capital manager: management fees on the $40M fund and carried interest from realised exits and liquidity events on portfolio companies (both acquisitions and ASX listings). GTM is sales-led and network-driven, sourced through direct relationships in the Western Australian life sciences ecosystem and government channels established via the IIF partnership. The customer segment is narrow by definition — early-stage life sciences ventures seeking both capital and commercialisation support — making the firm's investment pipeline its primary sales channel.

Short descriptiontext

Yuuwa Capital is a Perth-based venture capital firm specialising in early-stage life sciences commercialisation. Founded in 2009, it manages a $40M fund backed by the Australian Federal Government's IIF program, providing capital and board-level expertise to early-stage life sciences ventures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPerth, Australia
HQ citystring
Perth
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, life sciences investing, early stage capital, biotech commercialisation, startup funding
Industry1 code
PRIMARYFSANAGAF
Emerging Manager / Seeding Platforms (Multi-Manager)
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management Returns
TypeLicensing Royalties
Description

Yuuwa generates returns through equity stakes in portfolio companies. The firm was initially established in 2009 as the manager of a $40 million venture capital fund with investment from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. Returns are realised through exits of portfolio companies via acquisitions or IPOs.

yuuwa.com.au
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Yuuwa Capital is a specialist life sciences commercialisation and investment firm that manages a $40 million venture capital fund. The firm identifies new life sciences projects, helps founders and management start and scale their companies, and connects specialist early-stage investors with high-quality early-stage ventures. It provides both capital and direct hands-on commercialisation expertise, including board-level guidance, to portfolio companies in the life sciences sector.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Five FDA approved drugs and devices from team member James Williams
+2 more records
Product overview1 text field

Yuuwa Capital is a specialist life sciences commercialisation and investment firm that provides both expertise and capital to identify and scale portfolio companies in the life sciences sector. The firm operates as a venture capital manager, connecting specialist early stage investors with high quality early stage ventures in life sciences. Yuuwa does not offer distinct technology products or services itself; its portfolio consists of investee companies including AdAlta, Agworld, Fitgenes, iCentana, Nexgen Plants, and PolyActiva.

Product and service2 records
1Yuuwa $40 Million Life Sciences Venture Capital Fund
CategoryVenture capital fund
Description

A venture capital fund that invests in early-stage life sciences ventures in Australia, providing both capital and hands-on commercialisation support, board representation, and ongoing guidance to portfolio companies. Targeted at early-stage life sciences startup founders and management teams.

2Life Sciences Commercialisation Support
CategoryCommercialisation services
Description

Hands-on commercialisation expertise and operational support provided directly by Yuuwa's co-founders to portfolio companies. Includes concept-to-commercialisation guidance, executive/board roles support, and management of all phases of building and scaling life sciences ventures. Targeted at early-stage life sciences companies that Yuuwa has invested in.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Square Peg is a large Australian and Israeli venture capital firm. It is a broader incumbent in the Australian VC market, occasionally investing in health-tech adjacencies, but its primary focus is software/SaaS rather than life sciences.

TypeDirect peer
Description

Main Sequence Ventures is an Australian deep tech and science-backed venture firm (originating from the CSIRO Innovation Fund). It overlaps with Yuuwa in early-stage science-derived ventures and operates from a comparable Australian government-backed fund origin.

TypeBroad incumbent
Description

AirTree is a prominent Australian venture capital firm with a broad tech mandate. Operates as a larger incumbent in the Australian VC ecosystem where Yuuwa also sources deals and competes for talent.

TypeRegional player
Description

CP Ventures is an Australian deep tech and life sciences investor. Comparable to Yuuwa in early-stage science commercialisation, though operating from Sydney/Melbourne rather than Western Australia.

TypeDirect peer
Description

BioScience Managers was an Australian life sciences-focused investment manager; comparable to Yuuwa as a specialist life sciences manager raising capital from institutional and government sources and investing in Australian biomedical opportunities.

TypeDirect peer
Description

Brandon Capital is an Australian life sciences-focused venture capital firm managing the Medical Research Commercialisation Fund (MRCF) and related vehicles. It is the closest direct peer to Yuuwa given its parallel mandate of investing in and commercialising Australian life sciences ventures, often alongside government and institutional capital.

TypeBroad incumbent
Description

Blackbird is one of Australia's largest venture capital firms. While not life-sciences-specialist, it participates in Australian tech and life sciences rounds and competes for talent and limited partners in the same Australian VC ecosystem as Yuuwa.

TypeDirect peer
Description

OneVentures is an Australian venture capital firm with dedicated healthcare and life sciences funds. It competes for similar early- and growth-stage Australian life sciences opportunities and operates a comparable fund-of-funds and direct investment model.

9Uniseed
TypeDirect peer
Description

Uniseed is a venture fund operating between Australian universities and early-stage commercialisation, with a strong focus on life sciences and deep tech. Comparable to Yuuwa as an early-stage investor providing hands-on commercialisation support to research-derived ventures in Australia.

TypeBroad incumbent
Description

Artesian is an Australian alternative asset manager with venture capital, private credit and cleantech mandates. Comparable to Yuuwa as an Australian-headquartered fund manager but operates at much larger scale and broader sector mandate.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment17 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yuuwa Capital

Venture Capitalyuuwa.com.au

Yuuwa Capital is a Perth-based venture capital firm specialising in early-stage life sciences commercialisation. Founded in 2009, it manages a $40M fund backed by the Australian Federal Government's IIF program, providing capital and board-level expertise to early-stage life sciences ventures.

What Yuuwa Capital does

Yuuwa Capital is a specialist early-stage life sciences commercialisation and investment firm headquartered in Perth, Western Australia, founded in 2009. The firm was originally established as the manager of a $40 million venture capital fund with capital from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. Its stated function is to identify new projects, help founders and management teams start and scale companies in the life sciences sector, and connect specialist early-stage investors to high-quality life sciences ventures. There are no proprietary technology products or services — the "product" is the fund vehicle and the firm's operational support to portfolio companies.

Operationally, Yuuwa provides both capital and hands-on commercialisation expertise: direct equity investment, board representation, and ongoing portfolio support spanning concept-to-commercialisation activities. The team is led by co-founders Liddy McCall and James Williams, with documented track records including the founding of iCeutica Inc (acquired in 2011), co-founding and chairing ASX-listed Dimerix Limited (DXB), involvement in five FDA approved drugs and devices, board roles at AdAlta Limited (ASX:1AD), Argenica Ltd (ASX:AGN), Agworld Pty Ltd, Fitgenes Australia Limited, PolyActiva Pty Ltd, the Ear Science Institute of Australia, and the Perron Institute for Neurological and Translational Science. The disclosed portfolio comprises AdAlta, Agworld, Fitgenes, iCentana, Nexgen Plants, and PolyActiva.

Yuuwa's revenue model is that of a venture capital manager: management fees on the $40M fund and carried interest from realised exits and liquidity events on portfolio companies (both acquisitions and ASX listings). GTM is sales-led and network-driven, sourced through direct relationships in the Western Australian life sciences ecosystem and government channels established via the IIF partnership. The customer segment is narrow by definition — early-stage life sciences ventures seeking both capital and commercialisation support — making the firm's investment pipeline its primary sales channel.

Yuuwa Capital firmographics

Firmographics
Name
Yuuwa Capital
Legal name
Yuuwa
Website
https://yuuwa.com.au
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Yuuwa Capital is a Perth-based venture capital firm specialising in early-stage life sciences commercialisation. Founded in 2009, it manages a $40M fund backed by the Australian Federal Government's IIF program, providing capital and board-level expertise to early-stage life sciences ventures.
Ownership category
akta.pro rank

Yuuwa Capital industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAGAF
Emerging Manager / Seeding Platforms (Multi-Manager)
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital
  • Life sciences investing
  • Early stage capital
  • Biotech commercialisation
  • Startup funding

Where Yuuwa Capital is headquartered

Location

Headquarters

HQ city
Perth
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Yuuwa Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Revenue model

  1. Investment Management Returns: Yuuwa generates returns through equity stakes in portfolio companies. The firm was initially established in 2009 as the manager of a $40 million venture capital fund with investment from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors. Returns are realised through exits of portfolio companies via acquisitions or IPOs.

Go-to-market motion1 record

Distribution channels1 record

Yuuwa Capital product offering

Product offering

Core offering

Yuuwa Capital is a specialist life sciences commercialisation and investment firm that manages a $40 million venture capital fund. The firm identifies new life sciences projects, helps founders and management start and scale their companies, and connects specialist early-stage investors with high-quality early-stage ventures. It provides both capital and direct hands-on commercialisation expertise, including board-level guidance, to portfolio companies in the life sciences sector.

Product overview

Yuuwa Capital is a specialist life sciences commercialisation and investment firm that provides both expertise and capital to identify and scale portfolio companies in the life sciences sector. The firm operates as a venture capital manager, connecting specialist early stage investors with high quality early stage ventures in life sciences. Yuuwa does not offer distinct technology products or services itself; its portfolio consists of investee companies including AdAlta, Agworld, Fitgenes, iCentana, Nexgen Plants, and PolyActiva.

Differentiator

Problem solved

Functional benefit

Products and services

  • Yuuwa $40 Million Life Sciences Venture Capital Fund A venture capital fund that invests in early-stage life sciences ventures in Australia, providing both capital and hands-on commercialisation support, board representation, and ongoing guidance to portfolio companies. Targeted at early-stage life sciences startup founders and management teams.
  • Life Sciences Commercialisation Support Hands-on commercialisation expertise and operational support provided directly by Yuuwa's co-founders to portfolio companies. Includes concept-to-commercialisation guidance, executive/board roles support, and management of all phases of building and scaling life sciences ventures. Targeted at early-stage life sciences companies that Yuuwa has invested in.

Quantifiable outcome

  • Five FDA approved drugs and devices from team member James Williams
  • +2 more outcomes

Companies that use Yuuwa Capital

Customer profile

Segments1 record

Ideal customer profiles1 record

Yuuwa Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Yuuwa Capital partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Yuuwa Capital competitors and assessment

Company assessment

Broad incumbents

  • Square Peg Capital: Square Peg is a large Australian and Israeli venture capital firm. It is a broader incumbent in the Australian VC market, occasionally investing in health-tech adjacencies, but its primary focus is software/SaaS rather than life sciences.
  • AirTree Ventures: AirTree is a prominent Australian venture capital firm with a broad tech mandate. Operates as a larger incumbent in the Australian VC ecosystem where Yuuwa also sources deals and competes for talent.
  • Blackbird Ventures: Blackbird is one of Australia's largest venture capital firms. While not life-sciences-specialist, it participates in Australian tech and life sciences rounds and competes for talent and limited partners in the same Australian VC ecosystem as Yuuwa.
  • Artesian Capital Management: Artesian is an Australian alternative asset manager with venture capital, private credit and cleantech mandates. Comparable to Yuuwa as an Australian-headquartered fund manager but operates at much larger scale and broader sector mandate.

Direct peers

  • Main Sequence Ventures: Main Sequence Ventures is an Australian deep tech and science-backed venture firm (originating from the CSIRO Innovation Fund). It overlaps with Yuuwa in early-stage science-derived ventures and operates from a comparable Australian government-backed fund origin.
  • BioScience Managers (now IQ Group): BioScience Managers was an Australian life sciences-focused investment manager; comparable to Yuuwa as a specialist life sciences manager raising capital from institutional and government sources and investing in Australian biomedical opportunities.
  • Brandon Capital: Brandon Capital is an Australian life sciences-focused venture capital firm managing the Medical Research Commercialisation Fund (MRCF) and related vehicles. It is the closest direct peer to Yuuwa given its parallel mandate of investing in and commercialising Australian life sciences ventures, often alongside government and institutional capital.
  • OneVentures: OneVentures is an Australian venture capital firm with dedicated healthcare and life sciences funds. It competes for similar early- and growth-stage Australian life sciences opportunities and operates a comparable fund-of-funds and direct investment model.
  • Uniseed: Uniseed is a venture fund operating between Australian universities and early-stage commercialisation, with a strong focus on life sciences and deep tech. Comparable to Yuuwa as an early-stage investor providing hands-on commercialisation support to research-derived ventures in Australia.

Regional players

  • CP Ventures: CP Ventures is an Australian deep tech and life sciences investor. Comparable to Yuuwa in early-stage science commercialisation, though operating from Sydney/Melbourne rather than Western Australia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks2 records

Key highlights5 records

Customer concentration

Yuuwa Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yuuwa Capital leadership team

Management profile

Number of profiles

Profiles3 records

Yuuwa Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yuuwa Capital M&A and investment

M&A and investment

M&A

Investments17 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuuwa Capital

What does Yuuwa Capital do?

Yuuwa Capital is a specialist life sciences commercialisation and investment firm that manages a $40 million venture capital fund. The firm identifies new life sciences projects, helps founders and management start and scale their companies, and connects specialist early-stage investors with high-quality early-stage ventures. It provides both capital and direct hands-on commercialisation expertise, including board-level guidance, to portfolio companies in the life sciences sector.

Is Yuuwa Capital a public or private company?

Yuuwa Capital is a private company. It is classified as unknown and is currently operating.

When was Yuuwa Capital founded?

Yuuwa Capital was founded in 2009. It employs 1 to 10 people.

Where is Yuuwa Capital based?

Yuuwa Capital is headquartered in Perth, Australia, in the Oceania region.

How does Yuuwa Capital make money?

One revenue line is on record: investment Management Returns.

Who are Yuuwa Capital's main competitors?

Broad incumbents on record are Square Peg Capital, AirTree Ventures, Blackbird Ventures and Artesian Capital Management. Direct peers are Main Sequence Ventures, BioScience Managers (now IQ Group), Brandon Capital, OneVentures and Uniseed. CP Ventures is listed as a regional player.

Does Yuuwa Capital have an API?

No public API is recorded for Yuuwa Capital.

What industry is Yuuwa Capital in?

Yuuwa Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAGAF, Emerging Manager / Seeding Platforms (Multi-Manager). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AgFunderNewsAgworld, a Digital Communication Platform for Farmers, Snags AU$6 MillionAgworld, an Australian agricultural information platform, raised AU$6 million in a Series C round led by Reed Elsevier Ventures with Yuuwa Capital. The investment brings total equity to AU$12 million, and the company plans to use it to expand into North America and develop its farm management service.TechCrunchPassing 1 Million Downloads, Discovr Raises $1.1 Million; Launches On Mac App StoreDiscovr, a music discovery app, passed one million downloads and raised $1.1 million in seed funding led by Yuuwa Capital. It launched Discovr Music on the Mac App Store for $5, following an iPad app that drew 150K downloads in three days. Android versions are planned for release by year-end.TechCrunchPassing 1 Million Downloads, Discovr Raises $1.1 Million; Launches On Mac App StoreFilter Squad, the Australian startup behind the Discovr music and app discovery apps, announced it has crossed the 1 million downloads milestone and raised $1.1 million in seed funding led by Australian VC firm Yuuwa Capital. The company also launched Discovr Music for Mac, priced at $5, expanding its visual music discovery platform to desktop users after gaining 150,000 iPad downloads within three days of its January launch. Filter Squad, which won $25,000 at the Australian startup competition Tech23, plans to release Android versions of its Discovr apps by the end of the year.TechCrunchDealised Powers Group Buying Sites, Raises $6.5 MillionDealised raised $6.5 million in Series A funding from SingTel Innov8 and Yuuwa Capital. The Singapore company will use its regional Asian headquarters to drive global expansion and develop mobile group-buying solutions. It also appointed Jonathan Marchbank as CEO.